Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country
Issued Date
2023-03-01
Resource Type
ISSN
11753277
eISSN
1179187X
Scopus ID
2-s2.0-85147385213
Pubmed ID
36735211
Journal Title
American Journal of Cardiovascular Drugs
Volume
23
Issue
2
Start Page
173
End Page
183
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Cardiovascular Drugs Vol.23 No.2 (2023) , 173-183
Suggested Citation
Syeed M.S., Nonthasawadsri T., Nelson R.E., Chaiyakunapruk N., Nathisuwan S. Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country. American Journal of Cardiovascular Drugs Vol.23 No.2 (2023) , 173-183. 183. doi:10.1007/s40256-023-00570-z Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82373
Title
Integrating Real-World Evidence in Economic Evaluation of Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation in a Developing Country
Other Contributor(s)
Abstract
Objective: This study aimed to estimate the cost effectiveness of non-vitamin K oral anticoagulants (NOACs) compared with warfarin for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) in Thailand where suboptimal anticoagulation control is common. Materials and Methods: A hypothetical cohort of 65-year-old patients with NVAF and their disease progression was simulated in the Markov model. The following anticoagulant agents were used: warfarin, dabigatran, rivaroxaban, and apixaban. Warfarin with high, intermediate, and low time in therapeutic ranges (TTR) was used as the three different reference treatments. Baseline clinical events were obtained from a recently published real-world study in Thailand. A lifetime horizon was utilized in this model, and all analyses were performed from societal and healthcare perspectives. The results were reported as incremental cost-effectiveness ratios (ICERs) in 2021 US dollars per quality-adjusted life-year (QALY) gained. The sensitivity analyses were performed to assess the influence of parameter uncertainty. Results: Apixaban was a cost-effective intervention compared with warfarin with low and intermediate TTR groups. In the low TTR group, the ICERs were $779 and $816 per QALY gained from the societal and healthcare perspectives, respectively, and in the intermediate TTR group, the ICERs were $2038 and $3159 per QALY gained from the societal and healthcare perspectives, respectively. Both ICERs were below the accepted willingness-to-pay threshold ($4806) in the context of Thailand’s healthcare. Conclusions: In a developing country where suboptimal anticoagulation control is common, apixaban was the cost-effective alternative to warfarin for patients with both low and intermediate TTR control.